Aardvark Therapeutics (AARD) Current Assets (2024 - 2026)

Aardvark Therapeutics (AARD) has 3 years of Current Assets data on file, last reported at $93.6 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 39.45% year-over-year to $93.6 million; the trailing twelve-month figure through Mar 2026 stood at $93.6 million (down 39.45% YoY), and the FY2025 full-year result was $111.9 million, up 50.92% from the prior year.
• Current Assets declined to $93.6 million in Q1 2026, from $111.9 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $154.6 million in Q1 2025 to a low of $74.1 million in Q4 2024.
• A 3-year average of $118.0 million and a median of $120.5 million in 2025 frame the typical range for Current Assets.
• Across the five-year window, Current Assets soared 50.92% in 2025 and tumbled 39.45% in 2026, its largest moves.
• Tracing AARD's Current Assets over 3 years: stood at $74.1 million in 2024, then soared by 50.92% to $111.9 million in 2025, then dropped by 16.36% to $93.6 million in 2026.
• Business Quant data shows AARD's Current Assets at $93.6 million in Q1 2026, $111.9 million in Q4 2025, and $129.2 million in Q3 2025.